-
公开(公告)号：WO0216361A2
公开(公告)日：2002-02-28
申请号：PCT/US0141750
申请日：2001-08-17
Applicant: COR THERAPEUTICS INC , KYOWA HAKKO KOGYO KK , PANDEY ANJALI , SCARBOROUGH ROBERT M , MATSUNO KENJI , ICHIMURA MICHIO , NOMOTO YUGI , FUJIWARA SHIGEKI , IDE SHINICHI , TSUKIDA EIJI , IRIE JUNKO , ODA SHOJI
Inventor： PANDEY ANJALI , SCARBOROUGH ROBERT M , MATSUNO KENJI , ICHIMURA MICHIO , NOMOTO YUGI , FUJIWARA SHIGEKI , IDE SHINICHI , TSUKIDA EIJI , IRIE JUNKO , ODA SHOJI
IPC: A61P35/00 , C07D239/94 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D487/00
CPC classification number: C07D401/12 , C07D239/94 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12
Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibitng kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
Abstract translation: 本发明涉及对激酶的磷酸化具有抑制活性的含氮杂环化合物及其药学上可接受的盐，其抑制这些激酶的活性。 本发明还涉及抑制激酶和通过抑制激酶的磷酸化来治疗哺乳动物的疾病状态的方法。 本发明的一个特定方面提供了抑制PDGF受体的磷酸化以阻碍异常细胞生长和细胞游动的含氮杂环化合物及其药学上可接受的盐，以及预防或治疗细胞增殖性疾病如动脉硬化，血管性 重建，癌症和肾小球硬化。
-
公开(公告)号：WO0071507A3
公开(公告)日：2001-11-15
申请号：PCT/US0014196
申请日：2000-05-24
Applicant: COR THERAPEUTICS INC
Inventor： ZHU BING-YAN , SU TING , ZHAOZHONG JON JIA , SCARBOROUGH ROBERT M , SONG YONGHONG
IPC: A61P7/02 , A61K31/167 , A61K31/18 , A61K31/275 , A61K31/277 , A61K31/40 , A61K31/472 , A61K31/4725 , A61P9/00 , A61P9/04 , A61P9/10 , C07C311/16 , C07C311/18 , C07C311/40 , C07C311/44 , C07C311/46 , C07D207/16 , C07D217/22 , C07D401/06
CPC classification number: C07C311/40 , C07C311/16 , C07C311/18 , C07C311/44 , C07C311/46
Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
Abstract translation: 公开了与哺乳动物因子Xa具有活性的新型化合物，其盐和与其相关的组合物。 该化合物可用于体内或体内用于预防或治疗凝血障碍。
-
公开(公告)号：WO0071510A3
公开(公告)日：2001-08-30
申请号：PCT/US0014195
申请日：2000-05-24
Applicant: COR THERAPEUTICS INC
Inventor： SU TING , ZHU BING-YAN , KANE-MAGUIRE KIM , SCARBOROUGH ROBERT M , ZHANG PENGLIE
IPC: C07D213/74 , A61K31/18 , A61K31/198 , A61K31/341 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/4164 , A61K31/44 , A61K31/4406 , A61K31/4427 , A61K31/4453 , A61K31/472 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/5375 , A61K31/55 , A61P7/02 , A61P9/00 , A61P9/10 , A61P43/00 , C07C311/16 , C07C311/21 , C07C311/46 , C07D205/04 , C07D207/16 , C07D207/20 , C07D207/325 , C07D213/40 , C07D213/64 , C07D213/72 , C07D213/75 , C07D213/82 , C07D217/22 , C07D231/12 , C07D233/68 , C07D295/18 , C07D295/192 , C07D295/22 , C07D295/26 , C07D307/38 , C07D307/52 , C07D401/12 , A61K31/33 , C07D207/22 , C07D207/32
CPC classification number: C07D213/40 , C07C311/16 , C07C311/46 , C07D217/22 , C07D295/192 , C07D295/26 , C07D307/52 , C07D401/12
Abstract: Compounds of formula A - Y - D - E - G - J - Z - L in which D is direct link, a substutited or unsubstituted phenyl or napththyl group or a heterocyclic ring system; and the other variables are as defined in the claims, their salts and compositions relating thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
Abstract translation: 式A-Y-D-E-G-J-Z-L的化合物，其中D是直链，取代或未取代的苯基或萘乙基或杂环系统; 并且其它变量如权利要求中所定义，公开了其与其相关的盐和组合物具有抗哺乳动物因子Xa的活性。 该化合物在体外或体内可用于预防或治疗凝血障碍。
-
公开(公告)号：WO9901540A3
公开(公告)日：1999-03-25
申请号：PCT/US9813541
申请日：1998-07-01
Applicant: COR THERAPEUTICS INC , UNIV WASHINGTON , STROM DANIEL R , HACKER BETH , TOMLINSON JAMES A
Inventor： STROM DANIEL R , HACKER BETH , TOMLINSON JAMES A
CPC classification number: C12N9/88
Abstract: A DNA sequence encoding a human adenylyl cyclase is described. The amino acid sequence of the adenylyl cyclase is also described.
Abstract translation: 描述了编码人腺苷酸环化酶的DNA序列。 还描述了腺苷酸环化酶的氨基酸序列。
-
公开(公告)号：WO1998022500A2
公开(公告)日：1998-05-28
申请号：PCT/US1997022422
申请日：1997-11-21
Applicant: COR THERAPEUTICS, INC.
Inventor： COR THERAPEUTICS, INC. , JENKINS, Alison, L. , PHILLIPS, David, R.
IPC: C07K14/405
CPC classification number: C07K14/70546 , A61K38/00 , C07K14/70557
Abstract: The present invention describes a direct interaction between myosin and the cytoplasmic domain of membrane proteins, particularly the phosphorylated cytoplasmic domains of the beta -subunit of integrins. The invention provides methods of identifying agents which block integrin binding to myosin, methods of using agents which block integrin binding to myosin to modulate biological and pathological processes, and provides agents that block integrin mediated binding to myosin and thereby modulate related cellular or cellular component movement.
Abstract translation: 本发明描述了肌球蛋白和膜蛋白的细胞质结构域之间的直接相互作用，特别是整联蛋白β亚单位的磷酸化胞质结构域。 本发明提供鉴定阻断整合素与肌球蛋白结合的试剂的方法，使用阻断整合素结合肌球蛋白以调节生物学和病理学过程的试剂的方法，以及提供阻断整合素介导的结合肌球蛋白从而调节相关细胞或细胞成分运动的试剂 。
-
Patent Agency Ranking
公开(公告)号：WO1998016523A3
公开(公告)日：1998-04-23
申请号：PCT/US1997018291
申请日：1997-10-10
Applicant: COR THERAPEUTICS, INC.
Inventor： COR THERAPEUTICS, INC. , ZHU, Bing-Yan , SCARBOROUGH, Robert, M.
IPC: C07K05/06
-
公开(公告)号：WO1996040744A1
公开(公告)日：1996-12-19
申请号：PCT/US1996009290
申请日：1996-06-05
Applicant: COR THERAPEUTICS, INC. , MARLOWE, Charles, K. , SCARBOROUGH, Robert, M. , LAIBELMAN, Alan, M. , SINHA, Uma , ZHU, Bing-Yan
Inventor： COR THERAPEUTICS, INC.
IPC: C07K05/06
CPC classification number: C07K5/06 , A61K38/00 , C07K5/06078 , C07K5/06095 , C07K5/06139
Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
Abstract translation: 公开了与哺乳动物因子Xa有关的新型化合物，其盐和与其有关的组合物。 该化合物在体外或体内可用于预防或治疗凝血障碍。
-
18.发明申请PHARMACEUTICAL PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES 审中-公开用作蛋白激酶抑制剂的药用吡唑组合物
公开(公告)号：WO1996014843A2
公开(公告)日：1996-05-23
申请号：PCT/US1995014723
申请日：1995-11-09
Applicant: COR THERAPEUTICS, INC.
Inventor： COR THERAPEUTICS, INC. , GIESE, Neill, A. , LOKKER, Nathalie , LAIBELMAN, Alan, M. , SCARBOROUGH, Robert, M.
IPC: A61K31/415
CPC classification number: A61K31/455 , A61K31/415 , A61K31/4155 , A61K31/4439
Abstract: A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a compound of formula (I), wherein: R1 is lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, polyaromatic, polyaromatic carbonyl, polyheteroaromatic or polyheteroaromatic carbonyl; R2 is lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, lower hydrocarboyl, 5- or 6-membered heterocyclic aromatic carbonyl, polyaromatic or polyheteroaromatic; R3 is H or lower alkyl; R5 is H, lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, halogen, or cyano; and R6 is H or lower hydrocarboyl.
Abstract translation: 公开了选择性抑制激酶的方法，其包括将含有激酶的组合物与式（I）化合物接触，其中：R 1是低级烷基，低级烃基，芳基低级烷基，杂芳基低级烷基，5-或6- 多芳基，多芳基羰基，多杂芳基或多杂芳基羰基; R 2是低级烷基，低级烃基，芳基低级烷基，杂芳基低级烷基，5-或6-元杂环芳族，低级烃基，5-或6-元杂环芳族羰基，多芳族或多杂芳族; R3是H或低级烷基; R5是H，低级烷基，低级烃基，芳基低级烷基，杂芳基低级烷基，5-或6-元杂环芳族，卤素或氰基; R6为H或低级烃基。
-
公开(公告)号：WO1996013274A1
公开(公告)日：1996-05-09
申请号：PCT/US1995013940
申请日：1995-10-27
Applicant: COR THERAPEUTICS, INC.
Inventor： COR THERAPEUTICS, INC. , KING, Robert, S.
IPC: A61K38/36
CPC classification number: C12N9/6432 , C07K14/75 , C12Y304/21006 , Y10S530/829
Abstract: A process, as shown in the figure, for producing a highly purified preparation of an inhibited form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifiying the resulting inhibited activated blood factor.
Abstract translation: 如图所示，用于生产抑制形式的活化血液因子的高度纯化的制剂的方法需要提供含有目标血液因子的部分纯化的制剂，处理部分纯化的制剂以将血液因子转化为抑制 活化形式，然后净化所得的抑制的活化血液因子。
-
公开(公告)号：WO1996013259A3
公开(公告)日：1996-05-09
申请号：PCT/US1995013882
申请日：1995-10-26
Applicant: COR THERAPEUTICS, INC.
Inventor： COR THERAPEUTICS, INC. , GIESE, Neill, A. , LOKKER, Nathalie
IPC: A61K31/365
-
-
-
-
-
-
-
-
-
Search Results
476
records
(took 0.031 seconds)
